黄连素联合甲钴胺片治疗糖尿病脑病疗效观察及对血清miR-132-3p、miR-137表达与胰岛素抵抗的影响  

Observation on the Efficacy of Berberine Combined with Mecobalamin Tablets for Diabetic Encephalopathy and Its Effect on Serum miR-132-3p and miR-137 Expression and Insulin Resistance

作　　者：牛耕 周先炎 陶录岭 NIU Geng;ZHOU Xianyan;TAO Luling(Department of Traditional Chinese Medicine,Nanyang Second General Hospital,Nanyang Henan 473000,China)

机构地区：[1]南阳市第二人民医院中医科,河南南阳473000

出　　处：《新中医》2025年第7期115-119,共5页New Chinese Medicine

基　　金：河南省中医药科学研究专项课题(2022ZY2071)。

摘　　要：目的:观察黄连素联合甲钴胺片治疗糖尿病脑病疗效及对患者血清miR-132-3p、miR-137表达及胰岛素抵抗的影响。方法:选取2021年1月—2023年10月南阳市第二人民医院接受治疗的120例糖尿病脑病患者,按随机数字表法分为治疗组及对照组各60例。对照组接受常规治疗联合甲钴胺片治疗,治疗组在对照组基础上加用黄连素治疗。比较2组临床疗效及不良反应发生情况,比较2组治疗前后血糖、中医证候评分、血清miR-132-3p、miR-137表达、胰岛素抵抗指数的变化。结果:治疗组临床疗效总有效率为88.33%(53/60),对照组为73.33%(44/60),2组比较,差异有统计学意义(P<0.05)。治疗后,2组空腹血糖、餐后2 h血糖、糖化血红蛋白水平均较治疗前下降(P<0.05),治疗组上述3项水平均低于对照组(P<0.05)。治疗后,2组思维迟钝、倦怠嗜卧、脑转耳鸣、舌暗脉沉中医证候评分均较治疗前下降(P<0.05),治疗组上述4项评分均低于对照组(P<0.05)。治疗后,2组miR-132-3p、miR-137表达水平、胰岛素抵抗指数均较治疗前下降(P<0.05),治疗组miR-132-3p、miR-137表达水平、胰岛素抵抗指数均低于对照组(P<0.05)。治疗组不良反应发生率为8.33%(5/60),对照组不良反应发生率为3.33%(2/60),2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:黄连素联合甲钴胺片治疗糖尿病脑病疗效较好,能降低患者血清miR-132-3p、miR-137表达水平及胰岛素抵抗指数,安全性高。Objective:To observe the efficacy of berberine combined with Mecobalamin Tablets in the treatment of diabetic encephalopathy and its effect on patients'serum miR-132-3p and miR-137 expression,and insulin resistance.Methods:A total of 120 patients with diabetic encephalopathy treated at the Nanyang Second General Hospital from January 2021 to October 2023 were selected and divided into a treatment group and a control group according to the random number table method,with 60 cases in each group.The control group received conventional treatment combined with Mecobalamin Tablets,while the treatment group was additionally treated with berberine based on the control group.The clinical effects and adverse reactions in the two groups were compared,as well as the blood glucose,traditional Chinese medicine syndrome scores,the expression of serum miR-132-3p and miR-137,insulin resistance indexes before and after treatment.Results:The total effective rate of clinical effects in the treatment group was 88.33%(53/60),and that in the control group was 73.33%(44/60),with the difference between the two groups being significant(P<0.05).After treatment,the fasting blood glucose,2-hour postprandial blood glucose,and glycosylated hemoglobin levels in both groups were decreased compared with those before treatment(P<0.05),and the above three levels in the treatment group were lower than those in the control group(P<0.05).After treatment,the traditional Chinese medicine syndrome scores of slow thinking,fatigue and somnolence,dizziness and tinnitus,and dark tongue and deep pulse in the two groups were decreased compared with those before treatment(P<0.05),and the above four scores in the treatment group were lower than those in the control group(P<0.05).After treatment,the expression levels of miR-132-3p and miR-137 and the insulin resistance indexes in the two groups were decreased when compared with those before treatment(P<0.05),and the expression levels of miR-132-3p and miR-137 and the insulin resistance indexes in the treatment gr

关 键 词：糖尿病脑病 黄连素 甲钴胺片 miR-132-3p miR-137 胰岛素抵抗 

分 类 号：R259[医药卫生—中西医结合] R277.7[医药卫生—中医内科学]